US 12,281,305 B2
Compounds and methods for reducing prion expression
Susan M. Freier, San Diego, CA (US); Huynh-Hoa Bui, San Diego, CA (US); and Hien Thuy Zhao, San Diego, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Appl. No. 17/294,859
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
PCT Filed Nov. 21, 2019, PCT No. PCT/US2019/062681
§ 371(c)(1), (2) Date May 18, 2021,
PCT Pub. No. WO2020/106996, PCT Pub. Date May 28, 2020.
Claims priority of provisional application 62/770,386, filed on Nov. 21, 2018.
Prior Publication US 2022/0025366 A1, Jan. 27, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 31/7088 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/7088 (2013.01); C12N 2310/14 (2013.01); C12N 2310/31 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/34 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01); C12N 2320/35 (2013.01)] 29 Claims
 
1. A modified oligonucleotide according to the following chemical structure:

OG Complex Work Unit Chemistry
or a salt thereof.